S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.65%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.65%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.65%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.65%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)

Swedish Orphan Biovitrum AB (publ) Stock Price, News & Analysis (OTCMKTS:BIOVF)

$21.05
0.00 (0.00%)
(As of 11/28/2023 ET)
Compare
Today's Range
$21.05
$21.05
50-Day Range
$18.58
$21.05
52-Week Range
$18.25
$26.48
Volume
N/A
Average Volume
76 shs
Market Capitalization
$6.21 billion
P/E Ratio
24.20
Dividend Yield
N/A
Price Target
N/A

BIOVF stock logo

About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

BIOVF Stock Price History

BIOVF Stock News Headlines

Swedish Orphan Biovitrum AB BIOVF
Sobi has completed the issuances of series C shares
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Reminder: Invitation: Sobi's Q3 2023 report
Invitation: Sobi's Q3 2023 report
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Sobi KOL investor event: the journey for Vonjo®
Invitation: Sobi's Q2 2023 report
Sobi to present new data at the 2023 EHA congress
See More Headlines
Receive BIOVF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2023
Today
11/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BIOVF
CIK
N/A
Fax
N/A
Employees
1,612
Year Founded
2001

Profitability

Net Income
$261.43 million
Pretax Margin
19.83%

Debt

Sales & Book Value

Annual Sales
$1.86 billion
Cash Flow
$1.88 per share
Book Value
$8.91 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.21 billion
Optionable
Not Optionable
Beta
0.47

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Guido Oelkers (Age 58)
    CEO & President
    Comp: $22.78M
  • Mr. Henrik Stenqvist (Age 56)
    Chief Financial Officer
  • Mr. Torbjörn Hallberg (Age 54)
    General Counsel & Head of Legal Affairs
  • Mr. Daniel Rankin (Age 43)
    Head of Strategy & Corporate Development
  • Pablo de Mora (Age 55)
    Head of Global Marketing & Access
  • Ms. Lena Bjurner (Age 55)
    Head of Human Resources
  • Mr. Armin Reininger M.D. (Age 66)
    Ph.D., Senior Scientific & Medical Advisor
  • Mr. Norbert Oppitz (Age 56)
    Head of International
  • Mr. Sofiane Fahmy (Age 51)
    Head of Europe
  • Mr. Duane H. Barnes (Age 63)
    Head of North America














BIOVF Stock Analysis - Frequently Asked Questions

Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOVF shares.
View BIOVF analyst ratings
or view top-rated stocks.

How have BIOVF shares performed in 2023?

Swedish Orphan Biovitrum AB (publ)'s stock was trading at $21.15 on January 1st, 2023. Since then, BIOVF stock has decreased by 0.5% and is now trading at $21.05.
View the best growth stocks for 2023 here
.

Are investors shorting Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 570,700 shares, an increase of 8.5% from the October 15th total of 526,200 shares. Based on an average daily trading volume, of 400 shares, the days-to-cover ratio is currently 1,426.8 days.
View Swedish Orphan Biovitrum AB (publ)'s Short Interest
.

How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) posted its earnings results on Monday, October, 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by $0.04. The firm had revenue of $478.11 million for the quarter, compared to analyst estimates of $443.96 million. Swedish Orphan Biovitrum AB (publ) had a trailing twelve-month return on equity of 10.85% and a net margin of 13.05%.

How do I buy shares of Swedish Orphan Biovitrum AB (publ)?

Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:BIOVF) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -